Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001171843-20-005753
Filing Date
2020-08-07
Accepted
2020-08-07 18:52:47
Documents
54
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q bcrx20200630_10q.htm   iXBRL 10-Q 1349964
2 EXHIBIT 10.3 ex_196806.htm EX-10.3 1891
3 EXHIBIT 31.1 ex_196626.htm EX-31.1 13183
4 EXHIBIT 31.2 ex_196627.htm EX-31.2 13659
5 EXHIBIT 32.1 ex_196628.htm EX-32.1 5261
6 EXHIBIT 32.2 ex_196629.htm EX-32.2 4760
12 exh103_1.jpg GRAPHIC 188473
13 exh103_2.jpg GRAPHIC 62775
  Complete submission text file 0001171843-20-005753.txt   6419379

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA bcrx-20200630.xsd EX-101.SCH 50949
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE bcrx-20200630_cal.xml EX-101.CAL 34266
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE bcrx-20200630_def.xml EX-101.DEF 376930
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE bcrx-20200630_lab.xml EX-101.LAB 360494
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bcrx-20200630_pre.xml EX-101.PRE 390145
14 EXTRACTED XBRL INSTANCE DOCUMENT bcrx20200630_10q_htm.xml XML 957748
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-23186 | Film No.: 201085971
SIC: 2836 Biological Products, (No Diagnostic Substances)